Case report

Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease

Monica Dandapani, Brandon-Luke L. Seagle, Mary S. Chacho, Shohreh Shahabi

A 71-year-old woman with suspected endometrial cancer underwent robotic-assisted hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymph node dissection, and infracolic omentectomy revealing a stage II uterine carcinosarcoma with components of serous adenocarcinoma and undifferentiated spindle cell sarcoma. There was no evidence of distant metastasis at the time of surgery. However, pelvic washings were positive for malignant cells. She received adjuvant chemotherapy and vaginal cuff brachytherapy. Forty months later she developed a subcutaneous mass at the location of previous port site which was confirmed to be recurrence of the uterine primary. She subsequently developed additional distant metastases to the abdominal wall, lungs, and bone. Port site metastasis (PSM) was the earliest indicator of disseminated metastatic disease in this patient. We review challenges in the management of patients with PSM and propose that PSM be considered as a sign of systemic disease even when presenting as an apparently isolated recurrence.

© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
using a GORE® suture passer and the skin was closed with 4-0 Vicryl. Incisions healed without complication. Pathologic diagnosis was stage II uterine carcinosarcoma with components of serous adenocarcinoma, endometrioid adenocarcinoma, undifferentiated carcinoma, and undifferentiated spindle cell sarcoma. The tumor was 2.5 cm in maximum dimension in the uterine fundus with maximum depth of invasion of 15% of total myometrial thickness and had superficial cervical stromal invasion. Cytology of pelvic washings was positive for malignant cells. She received adjuvant high-dose-rate vaginal cuff brachytherapy (2100 cGy total dose in 3 weekly fractions) between six cycles of paclitaxel (135 mg/m²) and ifosfamide (1.6 g/m²) every three weeks, with three cycles of chemotherapy administered before brachytherapy and an additional three cycles after brachytherapy.

She remained without evidence of disease for 40 months, when she presented with a subcutaneous mass on the right lower quadrant at the location of a previous port-site. Computed tomography of the abdomen and pelvis demonstrated a 3.5 cm heterogeneous mass in the deep subcutaneous tissues of the right lower quadrant and was without evidence of other disease (Fig. 1). She underwent surgical resection of the mass, which extended to the fascia but not the peritoneum, which was not entered. Margins were clear. Pathology confirmed metastasis (high grade adenocarcinoma) consistent with her previous uterine primary (Fig. 2). She received external beam radiotherapy of 5990 cGy total dose to the right lower quadrant recurrence site. She declined systemic chemotherapy. Five months later, she had a new palpable lump at the right flank, 3 cm superior to the previous mass. This recurrence developed in the previously radiated field. Positron emission tomography (PET/CT) was performed and revealed a solitary focus of activity in the superficial right abdominal wall distinct from the previous recurrence site (Fig. 3). The mass was resected with clean margins and pathology again confirmed metastasis consistent with the primary diagnosis.

In the presence of severe back pain, she underwent another PET/CT two months after resection, which revealed new pulmonary nodules concerning for metastasis and L4 vertebral metastasis. She began palliative oral etoposide (50 mg alternating with 100 mg for days 1–21, then 7 days off, every 28 days) chemotherapy. She is currently alive 53 months from initial diagnosis.

3. Discussion

Many hypotheses have been proposed to explain the development of PSM including direct wound seeding by specimen removal or contaminated instruments, aerosolization of exfoliated cancer cells, the “chimney effect” caused by insufflation, and pneumoperitoneum, carbon dioxide, or tissue trauma altering the normal immunologic defenses at port sites (Curet, 2004). There is little evidence to support any practice to reduce PSM risk (Curet, 2004). The LAP2 trial reported a low PSM incidence of 0.24%, which is acceptable compared to laparotomy (Walker et al., 2012; Gücer et al., 2005). Furthermore, the LAP2 trial...
concluded that the use of MIS was safe regardless of pathological subtype (Walker et al., 2012).

Palomba et al. reviewed published data of PSM after staging for endometrial cancer (Palomba et al., 2012). PSM was isolated in 4 cases and developed with concurrent carcinomatosis in 8 cases. Isolated PSM were all endometrioid histology, high grade, and stage I or II at initial diagnosis. One patient declined excision and underwent palliative radiation plus hormone therapy before succumbing to disease 5 months later. One patient had excision followed by radiation and was disease free for 30 months before recurring and dying of disease 42 months after first recurrence. The other two patients had excision, radiation therapy and chemotherapy. Follow up data was unavailable for one patient. The second patient was disease free at 10 months after recurrence. Palomba et al. also concluded that apparently isolated PSM may represent occult, disseminated metastatic disease (Palomba et al., 2012).

Carlson et al. reported an interesting PSM at a right upper quadrant (RUQ) port-site used for laparoscopic cholecystectomy that was performed 6 months prior to the patient’s staging and diagnosis of stage IIIc serous ovarian cancer (Carlson et al., 2002). Twenty-seven months after laparoscopic surgical staging and cyto-reduction of the ovarian malignancy, she developed a PSM at a RUQ port-site from her prior laparoscopic cholecystectomy. The PSM was resected, and she was given platinum chemotherapy. Six months later she developed a pelvic recurrence and was treated with additional platinum chemotherapy. She subsequently remained disease free for three years prior to the report of her case. The apparently isolated RUQ PSM also preceded the development of additional metastatic disease despite treatment of the PSM with resection and systemic chemotherapy.

Uterine carcinosarcoma, although initially considered to be a sarcoma, is now recognized as an advanced carcinoma that undergoes an epithelial-to-mesenchymal transformation (Cantrell et al., 2015). It is one of the most aggressive types of uterine pathologies, associated with high recurrence rates and a 5-year survival of 33–39% (Cantrell et al., 2015). In our case, the patient developed an isolated uterine carcinosarcoma PSM after a 40 month disease free interval but before any indication of systemic disease. Later, she developed an additional abdominal wall metastasis, as well as suspected pulmonary and bone metastases. We believe that her PSM was an early indication of occult disseminated disease. We propose that when patients develop an apparently isolated PSM, although additional metastases may not yet be evident by imaging, the presence of PSM indicates high risk for progression of disease and warrants systemic treatment in additional to local excision and/or radiation. We propose that patients with apparently isolated PSM without evidence of other metastatic disease require systemic chemotherapy in addition to excision and/or radiation therapy to the site of recurrence. PSM of carcinosarcoma indicates a poor prognostic condition for the patient and palliative discussions should be initiated. Best management of isolated PSM is broadly relevant to Gynecologic Oncology practice. All patients undergoing laparoscopic surgery for cancer are at risk for PSM. Case reports, case series and literature reviews informing expert opinion will likely remain the highest level of evidence for the clinical dilemma of isolated PSM.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Disclaimer

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-In-Chief of this journal on request. This case report was exempt from IRB review.

Acknowledgments

The authors wish to thank Jennifer K. Stedman, MPH, PA-C for the assistance in obtaining patient consent.

References

Cantrell, L.A., Blank, S.V., Duska, L.R., 2015. Uterine carcinosarcoma: a review of the literature. Gynecol. Oncol. Mar 21. [http://dx.doi.org/10.1016/j.ygyno.2015.03.041] [Epub ahead of print]).

Carlson, N.L., Krivak, T.C., Winter 3rd, W.E., Macri, C.I., 2002. Port site metastasis of ovarian carcinoma from laparoscopic surgery for benign disease. Gynecol. Oncol. 85 (3), 529–531 (Jun).

Curet, M.J., 2004. Port site metastases. Am. J. Surg. 187 (6), 705–712 (Jun).

Gücer, F., Oz-Puyan, F., Yilmaz, O., Mülayim, N., Balkanlı-Kaplan, P., Yüce, M.A., 2005. Endometrial carcinoma with laparotomy wound recurrence: complete remission following surgery and chemotherapy consisting of paclitaxel and carboplatin. Int. J. Gynecol. Cancer 15 (6), 1195–1198 (Nov-Dec).

Lönnerforss, C., Bossmar, T., Persson, J., 2013. Port-site metastases following robot-assisted laparoscopic surgery for gynecological malignancies. Acta Obstet. Gynecol. Scand. 92 (12), 1361–1368 (Dec, Epub 2013 Oct 7).

National Comprehensive Cancer Network. 2014. NCCN Clinical Practice Guidelines in Oncology Endometrial Cancer Version 1.2013 [Internet]. National Comprehensive Cancer Network, Fort Washington, PA (cited 2014 Aug 20). Available from: http://www.nccn.org/).

Palomba, S., Falbo, A., Russo, T., La Sala, G.B., 2012. Port-site metastasis after laparoscopic surgical staging of endometrial cancer: a systematic review of the published and unpublished data. J. Minim. Invasive Gynecol. 19 (4), 531–537 (Jul-Aug).
Walker, J.L., Piedmonte, M.R., Spirtos, N.M., Eisenkop, S.M., Schlaerth, J.B., Mannel, R.S., Spiegel, G., Barakat, R., Pearl, M.L., Sharma, S.K., 2009. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group study LAP2. J. Clin. Oncol. 27 (32), 5331–5336 (Nov 10, Epub 2009 Oct 5).
Walker, J.L., Piedmonte, M.R., Spirtos, N.M., Eisenkop, S.M., Schlaerth, J.B., Mannel, R.S., Barakat, R., Pearl, M.L., Sharma, S.K., 2012. Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: gynecologic oncology group LAP2 study. J. Clin. Oncol. 30 (7), 695–700 (Mar 1, Epub 2012 Jan 30).
Zivanovic, O., Sonoda, Y., Diaz, J.P., Levine, D.A., Brown, C.L., Chi, D.S., Barakat, R.R., Abu-Rustum, N.R., 2008. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol. Oncol. 111 (3), 431–437 (Dec, Epub 2008 Oct 16).